Naphthostyrils
    3.
    发明授权
    Naphthostyrils 失效
    萘妥拉明

    公开(公告)号:US06531598B1

    公开(公告)日:2003-03-11

    申请号:US10224022

    申请日:2002-08-20

    IPC分类号: C07D41314

    摘要: Disclosed are novel naphthostyrils of formula These compounds inhibit cyclin-dependent kinases (CDKs), in particular CDK2. These compounds and their pharmaceutically acceptable salts and esters are anti-proliferative agents useful in the treatment or control of cell proliferative disorders, in particular cancer. Also disclosed are pharmaceutical compositions containing such compounds, methods for the treatment and/or prevention of cancer using such compositions, and intermediates useful in the preparation of the compounds of formula I.

    摘要翻译: 公开了新颖的式萘普通抗坏血酸的这些化合物抑制细胞周期蛋白依赖性激酶(CDK),特别是CDK2。 这些化合物及其药学上可接受的盐和酯是可用于治疗或控制细胞增殖性疾病,特别是癌症的抗增殖剂。 还公开了含有这些化合物的药物组合物,使用这种组合物治疗和/或预防癌症的方法,以及可用于制备式I化合物的中间体。

    5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
    5.
    发明授权
    5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones 失效
    5,8-二氢-6H-吡啶并[2,3-d]嘧啶-7-酮

    公开(公告)号:US07098332B2

    公开(公告)日:2006-08-29

    申请号:US10731594

    申请日:2003-12-08

    IPC分类号: C07D471/04 A61K31/519

    CPC分类号: C07D471/04

    摘要: The invention provides 5,8-dihydro-6H-pyrido[2,3-d]pyrimidin-7-one compounds that are selective inhibitors of KDR and FGFR kinases, and are useful in the treatment of cancers. The compounds have the generic structure I where Ar, Ar′, and R1 are as set forth in the present specification. The invention also provides pharmaceutical compositions containing these compounds and methods for their use.

    摘要翻译: 本发明提供作为KDR和FGFR激酶的选择性抑制剂的5,8-二氢-6H-吡啶并[2,3-d]嘧啶-7-酮化合物,并且可用于治疗癌症。 化合物具有通式结构I,其中Ar,Ar'和R 1如本说明书所述。 本发明还提供含有这些化合物的药物组合物及其使用方法。

    4-alkenyl-and 4-alkynyloxindoles
    8.
    发明授权
    4-alkenyl-and 4-alkynyloxindoles 失效
    4-链烯基和4-炔氧基吲哚

    公开(公告)号:US06303793B1

    公开(公告)日:2001-10-16

    申请号:US09566054

    申请日:2000-05-05

    IPC分类号: C07D20934

    摘要: Disclosed are novel 4-alkenyl- and 4-alkynyl oxindoles having the formula and the pharmaceutically acceptable salts thereof, wherein R1, R2, R3, a, b, and X are as defined herein. These compounds inhibit cyclin-dependent kinases (CDKs), in particular CDK2. These compounds and their pharmaceutically acceptable salts, and prodrugs of said compounds, are anti-proliferative agents useful in the treatment or control of cell proliferative disorders, in particular cancer, more particularly, the treatment or control of breast and colon tumors. Also disclosed are pharmaceutical compositions containing the compounds of formula I and II as well as intermediates useful in the preparation of the compounds of formula I and II.

    摘要翻译: 公开了具有下式的新的4-烯基 - 和4-炔基羟基吲哚及其药学上可接受的盐,其中R1,R2,R3,a,b和X如本文所定义。 这些化合物抑制细胞周期蛋白依赖性激酶(CDK),特别是CDK2。 这些化合物及其药学上可接受的盐和所述化合物的前药是用于治疗或控制细胞增殖性疾病,特别是癌症的抗增殖剂,更具体地,涉及乳腺癌和结肠肿瘤的治疗或控制。 还公开了含有式I和II化合物的药物组合物以及可用于制备式I和II化合物的中间体。

    Imidazo pyrazines
    10.
    发明授权
    Imidazo pyrazines 有权
    咪唑吡嗪

    公开(公告)号:US08673905B2

    公开(公告)日:2014-03-18

    申请号:US13415868

    申请日:2012-03-09

    摘要: Compounds of formula and pharmaceutically acceptable salts thereof are described, as well as the pharmaceutical compositions containing said compounds and their pharmaceutically acceptable salts, and the use of said compounds and pharmaceutical compositions for the treatment, control or amelioration of AML.

    摘要翻译: 本发明描述了式及其药学上可接受的盐的化合物,以及含有所述化合物及其药学上可接受的盐的药物组合物,以及所述化合物和药物组合物用于治疗,控制或改善AML的用途。